Genetic Diversity and in vitro Activity of Aztreonam/Avibactam and Ceftazidime/Avibactam Against Carbapenem-Resistant Enterobacterales: A Multi-Center Study in Southwest China

被引:4
|
作者
Sun, Shan [1 ]
Chen, Kai [2 ]
Kong, Xuehua [2 ]
Tian, Wenjun [3 ]
Niu, Siqiang [1 ]
机构
[1] Chongqing Med Univ, Dept Lab Med, Affiliated Hosp 1, Chongqing, Peoples R China
[2] Chongqing Med Univ, Coll Lab Med, Chongqing, Peoples R China
[3] Shandong Univ, Shandong Prov Hosp, Cheeloo Coll Med, Dept Clin Lab Med, Jinan, Shandong, Peoples R China
来源
基金
中国国家自然科学基金;
关键词
carbapenem-resistant Enterobacterales; carbapenemase genes; aztreonam/avibactam; ceftazidime/avibactam; KLEBSIELLA-PNEUMONIAE; MOLECULAR EPIDEMIOLOGY; ANTIBIOTIC-RESISTANCE; AZTREONAM-AVIBACTAM; INFECTION; STRAINS; CRE;
D O I
10.2147/IDR.S357396
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Purpose: This study aimed to understand the distribution characteristics of carbapenemase genes and assess the antimicrobial activities of aztreonam/avibactam (ATM/AVI) and ceftazidime/avibactam (CAZ/AVI) against carbapenem-resistant Enterobacterales (CRE) isolates in Chongqing, Southwest China. Methods: CRE isolates and their clinical information were collected from 22 hospitals covering all the five regions across Chongqing between January 1, 2016 and December 31, 2017. PCR was used to screen for common carbapenemase genes. And minimum inhibitory concentrations (MICs) were determined by broth microdilution method. Results: A total of 312 unduplicated CRE isolates (eg, 206 Klebsiella pneumoniae, 43 Escherichia coli, and 42 Enterobacter cloacae) were collected during the two-year study period. Among these CRE isolates, 92.3% carried carbapenemase genes, with a majority of isolates carrying single bla(KPC-2) (47.1%) or single bla(NDM/IPM) (36.2%) and 8.9% of isolates carrying two or three carbapenemase genes. Notably, 95.6% (197/206) K. pneumoniae, 86.0% (37/43) E. coli and 88.1% (37/42) E. cloacae harbored carbapenemase genes. In addition, bla(KPC-2) was prevalent in K. pneumoniae (70.4%), while bla(NDM) was predominant in E. coli (83.7%) and E. cloacae (78.6%). Besides, only metallo-beta-lactamase (MBL) genes were detected in the CRE isolates from children. Overall, 0.0%, 48.1%, 59.0%, 61.5% and 63.1% of the CRE isolates were resistant to ATM/AVI, CAZ/AVI, nitrofurantoin, amikacin and trimethoprim/sulfamethoxazole, respectively. 99.7% of the total 312 isolates could be killed by ATM/AVI with the MIC 1 mu g/mL, whereas CAZ/AVI showed good antibacterial activity (98.0% susceptible) against the bla(KPC-2)-carriers with the MIC50/90 values of 1/4 mu g/mL. Conclusion: The distribution features of carbapenemase genes in Chongqing were comprehensively illustrated in terms of species and sources of CRE for the first time in this multi-center study that covered all the geographical locations across Chongqing. ATM/AVI showed superior activity against all CRE isolates regardless of their genotype, whereas CAZ/AVI was active against almost all KPC-producers.
引用
收藏
页码:2243 / 2251
页数:9
相关论文
共 50 条
  • [41] In vitro activity of cefiderocol against comparators (ceftazidime-avibactam, ceftazidime-avibactam/aztreonam combination, and colistin) against clinical isolates of meropenem-resistant Klebsiella pneumoniae from India
    Borde, Kalyani
    Kareem, M. A.
    Sharma, Ratna Mani
    Dass, S. Manick
    Ravi, Vedantham
    Mathai, Dilip
    Powell, Eleanor A.
    MICROBIOLOGY SPECTRUM, 2023, 11 (05):
  • [42] In vitro activity of aztreonam/avibactam against isolates of Enterobacterales collected globally from ATLAS in 2019
    Rossolini, Gian Maria
    Stone, Gregory
    Kantecki, Michal
    Arhin, Francis F.
    JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE, 2022, 30 : 214 - 221
  • [43] Rapid emergence of ceftazidime-avibactam resistance among carbapenem-resistant Enterobacterales in a tertiary-care hospital in Taiwan
    Lee, Jia-Arng
    Du, Shin-Hei
    Lee, Tai-fen
    Huang, Yu-Shan
    Liao, Chun-Hsing
    Huang, Yu-Tsung
    Hsueh, Po-Ren
    JOURNAL OF INFECTION, 2023, 86 (01) : 92 - 95
  • [44] In Vitro Activities of Ceftazidime-Avibactam and Aztreonam-Avibactam at Different Inoculum Sizes of Extended-Spectrum β-Lactam-Resistant Enterobacterales Blood Isolates
    Bae, Moonsuk
    Kim, Taeeun
    Park, Joung Ha
    Bae, Seongman
    Sung, Heungsup
    Kim, Mi-Na
    Jung, Jiwon
    Kim, Min Jae
    Kim, Sung-Han
    Lee, Sang-Oh
    Choi, Sang-Ho
    Kim, Yang Soo
    Chong, Yong Pil
    ANTIBIOTICS-BASEL, 2021, 10 (12):
  • [45] The Comparative Efficacy of Ceftazidime-Avibactam with or without Aztreonam vs Polymyxins for Carbapenem-resistant Enterobacteriaceae Infections: A Prospective Observational Cohort Study
    Vijayakumar, M.
    Selvam, Velmurugan
    Renuka, M. K.
    Rajagopalan, Ram Eachambadi
    INDIAN JOURNAL OF CRITICAL CARE MEDICINE, 2023, 27 (12) : 923 - 929
  • [46] Identifying Spectra of Activity and Therapeutic Niches for Ceftazidime-Avibactam and Imipenem-Relebactam against Carbapenem-Resistant Enterobacteriaceae
    Haidar, Ghady
    Clancy, Cornelius J.
    Chen, Liang
    Samanta, Palash
    Shields, Ryan K.
    Kreiswirth, Barry N.
    Nguyen, M. Hong
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2017, 61 (09)
  • [47] Use of Ceftazidime-Avibactam for Suspected or Confirmed Carbapenem-Resistant Organisms in Children: A Retrospective Study
    Meng, Haiyang
    Zhao, Yongmei
    An, Qi
    Zhu, Baoling
    Cao, Zhe
    Lu, Jingli
    INFECTION AND DRUG RESISTANCE, 2023, 16 : 5815 - 5824
  • [48] Ceftazidime-Avibactam Is Superior to Other Treatment Regimens against Carbapenem-Resistant Klebsiella pneumoniae Bacteremia
    Shields, Ryan K.
    Nguyen, M. Hong
    Chen, Liang
    Press, Ellen G.
    Potoski, Brian A.
    Marini, Rachel V.
    Doi, Yohei
    Kreiswirth, Barry N.
    Clancy, Cornelius J.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2017, 61 (08)
  • [49] Clinical Outcomes in Carbapenem-Resistant Enterobacteriaceae Infections Treated With Ceftazidime-Avibactam: A Single-Center Observational Study
    Rathish, Balram
    Wilson, Arun
    Warrier, Anup
    Prakash, Shilpa
    Babu, Rachana
    Joy, Sonya
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2021, 13 (02)
  • [50] Ceftazidime-avibactam with or without Aztreonam vs Polymyxin-based Combination Therapy for Carbapenem-resistant Enterobacteriaceae: A Retrospective Analysis
    Prayag, Parikshit S.
    Patwardhan, Sampada A.
    Panchakshari, Shweta
    Sambasivam, Ramya
    Dhupad, Surabhi
    Soman, Rajeev N.
    Prayag, Amrita P.
    INDIAN JOURNAL OF CRITICAL CARE MEDICINE, 2023, 27 (06) : 444 - 450